Matthew K. Fox

EVQLV leverages advances in computation to revolutionize the design and development of therapeutic antibodies. We work with partners at the discovery stage to accelerate the speed of antibody discovery. For those collaborators who have preclinical, clinical, or commercial assets, we support the optimization of antibody candidates, develop assets that expand IP protection, and design next generation and innovative immunotherapies. All of our work is performed at accelerated speeds and scale only feasible by leveraging computational tools that learn from massive and diverse datasets.

Patients who experience complex high risk surgery or are expected to heal slowly are often managed with a wound drain. Current drain output monitoring practices are manual - nurses (in the hospital) and patients (at home) eyeball the color and volume. Inaccurate data means drains are usually installed longer than necessary and nurses and patients miss early onset of complications - infection, leaks, excessive bleeding and blockages. This results in longer lengths of stay and increased readmission rates. Medsix plans to sell a disposable sensor with predictive analytics that can be attached to any wound drain to automate monitoring. This will address the needs of patients - detect complications earlier, remove drains sooner and reduce overall recovery time; providers - improve clinical decision making and create a standard for wound drain output; and payers - shorten length of stay and decrease readmission rates. Petri Bio / Pillar VCs Bioengineering Accelerator MassMEDIC IGNITE Program JLABS Boston MIT Sloan Healthcare Innovation Competition Finalist AlphaLab Healthcare Safety Challenge Finalist MIT Hacking Medicine Winner FallingWalls Berlin Finalist MIT NSF I-Corp Awardee MassMEDIC DeviceTalks Startup Showcase SAGES 2020 Emerging Technology Session MDG Pitchfest 2020 J&J Innovation Pavilion Advamed Medtech Conference 2019

Injections as easy as pushing a button.

EVQLV leverages advances in computation to revolutionize the design and development of therapeutic antibodies. We work with partners at the discovery stage to accelerate the speed of antibody discovery. For those collaborators who have preclinical, clinical, or commercial assets, we support the optimization of antibody candidates, develop assets that expand IP protection, and design next generation and innovative immunotherapies. All of our work is performed at accelerated speeds and scale only feasible by leveraging computational tools that learn from massive and diverse datasets.

Patients who experience complex high risk surgery or are expected to heal slowly are often managed with a wound drain. Current drain output monitoring practices are manual - nurses (in the hospital) and patients (at home) eyeball the color and volume. Inaccurate data means drains are usually installed longer than necessary and nurses and patients miss early onset of complications - infection, leaks, excessive bleeding and blockages. This results in longer lengths of stay and increased readmission rates. Medsix plans to sell a disposable sensor with predictive analytics that can be attached to any wound drain to automate monitoring. This will address the needs of patients - detect complications earlier, remove drains sooner and reduce overall recovery time; providers - improve clinical decision making and create a standard for wound drain output; and payers - shorten length of stay and decrease readmission rates. Petri Bio / Pillar VCs Bioengineering Accelerator MassMEDIC IGNITE Program JLABS Boston MIT Sloan Healthcare Innovation Competition Finalist AlphaLab Healthcare Safety Challenge Finalist MIT Hacking Medicine Winner FallingWalls Berlin Finalist MIT NSF I-Corp Awardee MassMEDIC DeviceTalks Startup Showcase SAGES 2020 Emerging Technology Session MDG Pitchfest 2020 J&J Innovation Pavilion Advamed Medtech Conference 2019

Techstars helps founders scale their startups into world-changing businesses. Founded in 2006, Techstars is on a mission to invest in startups to enable more capital to flow to more entrepreneurs around the world in order to deliver exceptional returns to our investors. We do this by operating accelerator programs and venture capital funds, as well as by connecting startups, investors, corporations, and cities to help build thriving startup communities. Our results show why Techstars is Better for Founders than any other global accelerator: On average, 74.5% of Techstars companies will raise money within 3 years of their program; 18.5% of Techstars portfolio companies have exited 5 years after their program and 31.1% after eight years. (PitchBook June 2023)

Injections as easy as pushing a button.